NASDAQ$ACRS
Aclaris Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Aclaris Therapeutics reported a net loss, but is progressing with clinical trials and expects key data readouts soon.
Aclaris Therapeutics reported a net loss of $29.3 million for Q3 2023, compared to a net loss of $20.0 million for Q3 2022. Total revenue was $9.3 million, down from $19.0 million in the prior year, primarily due to a one-time upfront payment received in 2022. The company is focused on advancing its clinical development programs, with topline data expected for zunsemetinib in rheumatoid arthritis this month and ATI-1777 in atopic dermatitis around year-end 2023.
- Aclaris Therapeutics reported a net loss of $29.3 million for the third quarter of 2023.
- Total revenue for Q3 2023 was $9.3 million, compared to $19.0 million for Q3 2022.
- The company continues to advance its clinical development programs, with key data readouts expected soon.
- Aclaris anticipates its cash, cash equivalents, and marketable securities will be sufficient to fund operations through the end of 2025.
Headline financials
Revenue & EPS history
Aclaris Therapeutics · Revenue · Quarterly
$9.28M
Revenue by segment
Aclaris Therapeutics · $9.28M total across 2 segments · Q3 2023
- Licensing$8.58M-52.1%92.4%
- Contract research$705K-35.3%7.6%
Forward guidance
Aclaris anticipates its cash, cash equivalents and marketable securities as of September 30, 2023 will be sufficient to fund its operations through the end of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-0.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-0.7%
Avg return
30 days after
38%
16 / 42 earnings
Positive
+22.7%
Q4 2018
Best reaction
-15.3%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | +1.9% | -8.8% | |
| Q4 2025 | -5.2% | -8.2% | +6.3% | |
| Q3 2025 | -4.7% | -9.7% | +23.7% | |
| Q1 2025 | -0.8% | -3.8% | +9.9% | |
| Q4 2024 | -7.1% | -8.1% | -24.3% | |
| Q3 2024 | +10.4% | +18.5% | +77.5% | |
| Q2 2024 | -4.1% | -6.6% | -4.1% | |
| Q1 2024 | -6.9% | -10.7% | -21.4% | |
| Q4 2023 | -1.7% | +2.5% | +2.5% | |
| Q3 2023 | +0.9% | -11.5% | -81.0% | |
| Q2 2023 | -12.1% | -16.5% | -23.4% | |
| Q1 2023 | -7.8% | -12.1% | +4.5% | |
| Q4 2022 | -4.9% | -1.8% | -36.9% | |
| Q3 2022 | +4.3% | +9.3% | -0.2% | |
| Q2 2022 | +18.1% | +26.8% | +20.6% | |
| Q1 2022 | -8.9% | -4.5% | +35.3% | |
| Q4 2021 | +14.3% | +11.3% | +33.5% | |
| Q3 2021 | -12.4% | -11.0% | -31.4% | |
| Q2 2021 | +4.1% | +1.4% | +21.2% | |
| Q1 2021 | -2.2% | -8.6% | -8.8% | |
| Q4 2020 | +7.8% | +12.5% | +11.4% | |
| Q3 2020 | +7.0% | +7.5% | +0.8% | |
| Q2 2020 | +11.3% | +12.8% | +9.7% | |
| Q1 2020 | +12.7% | +10.3% | +13.5% | |
| Q4 2019 | -14.0% | -20.3% | -18.2% | |
| Q3 2019 | +20.4% | +11.7% | +2.5% | |
| Q2 2019 | -11.8% | -18.8% | -1.0% | |
| Q1 2019 | -11.2% | -14.7% | -29.0% | |
| Q4 2018 | +22.7% | +8.7% | -7.8% | |
| Q3 2018 | -1.8% | -13.2% | -29.8% | |
| Q2 2018 | -4.6% | -3.9% | -11.9% | |
| Q1 2018 | -0.5% | +4.2% | +1.4% | |
| Q4 2017 | -6.7% | -12.5% | -18.4% | |
| Q3 2017 | -5.7% | -3.2% | -7.9% | |
| Q2 2017 | -0.1% | -7.1% | +1.4% | |
| Q1 2017 | +6.3% | +5.8% | +0.6% | |
| Q4 2016 | -4.9% | -5.2% | +5.8% | |
| Q3 2016 | -1.0% | -2.7% | +39.7% | |
| Q2 2016 | +3.1% | +7.0% | +15.0% | |
| Q1 2016 | -15.3% | — | — | |
| Q4 2015 | -3.9% | — | — | |
| Q3 2015 | +5.8% | — | — | |
| Q2 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro